Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM ESTCompany ParticipantsRoger Jeffs - CEO ...
If you’re one of the 35 million people living with a chronic lung disease in the United States, the form of treatment you ...
Operator: Good morning, and welcome to BiomX Third Quarter 2025 Financial Results and Program Update Conference Call.
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
BiomX Inc (PHGE) progresses in clinical trials for BX004 and BX011, despite facing financial constraints and a temporary FDA ...
Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success BiomX expects FDA feedback on BX004 clinica ...
Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease November 9:00 ...
Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and ...
21d
Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants
Jefferies, Piper Sandler, and Guggenheim Securities are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as the lead manager, and Citizens Capital Markets and H.C.
Dublin, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The "United States Nebulizer Market Report by Type, Modality, Applications, End Use, States and Company Analysis, 2025-2033" report has been added to ...
The FDA has approved an expanded indication for risperidone (Uzedy, Teva) extended-release injectable suspension, allowing it to be used for the maintenance treatment of bipolar I disorder in adults, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback